Javascript must be enabled to continue!
Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation
View through CrossRef
<b><i>Introduction:</i></b> Alpha-adrenergic blockers are now the cornerstone medication in management of lower urinary tract symptom (LUTS); however, the associated treatment-related abnormal ejaculation could be a bothersome event. This is a comparative study among different methods of tamsulosin administration in terms of efficacy, recoverability of ejaculatory function, and quality of life (QoL) in men with tamsulosin-related abnormal ejaculation. <b><i>Patients and Methods:</i></b> Sexually active men receiving tamsulosin for LUTS who were bothered by treatment-related abnormal ejaculation following initiation of tamsulosin were randomized into 3 groups; group A received intermittent-full-standard-dose, group B received low-dose-tamsulosin, and group C received full-standard-dose tamsulosin The status of ejaculatory function, IPSS, QoL score, and Q-Max were measured at baseline and 3 months later. <b><i>Results:</i></b> A total of 93 men with mean age of 53.1 years were included in the study, 3-months after randomization, statistically significant improvements in IPSS, QoL index, and Q-Max in comparison to pre-treatment levels were noted. Restoration of normal ejaculation was reported by 74.1 and 90.3% of patients in group A and B, respectively, versus none in group C. The QoL score was significant when comparing group A to the other groups; finally, the Q-Max was significant when comparing group C to the other groups. <b><i>Conclusion:</i></b> For patients bothered by tamsulosin-related abnormal ejaculation, a significant improvement in the QoL, without deviation from the therapeutic purpose of treatment, can be achieved by administration of 0.4 mg tamsulosin every other day.
Title: Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation
Description:
<b><i>Introduction:</i></b> Alpha-adrenergic blockers are now the cornerstone medication in management of lower urinary tract symptom (LUTS); however, the associated treatment-related abnormal ejaculation could be a bothersome event.
This is a comparative study among different methods of tamsulosin administration in terms of efficacy, recoverability of ejaculatory function, and quality of life (QoL) in men with tamsulosin-related abnormal ejaculation.
<b><i>Patients and Methods:</i></b> Sexually active men receiving tamsulosin for LUTS who were bothered by treatment-related abnormal ejaculation following initiation of tamsulosin were randomized into 3 groups; group A received intermittent-full-standard-dose, group B received low-dose-tamsulosin, and group C received full-standard-dose tamsulosin The status of ejaculatory function, IPSS, QoL score, and Q-Max were measured at baseline and 3 months later.
<b><i>Results:</i></b> A total of 93 men with mean age of 53.
1 years were included in the study, 3-months after randomization, statistically significant improvements in IPSS, QoL index, and Q-Max in comparison to pre-treatment levels were noted.
Restoration of normal ejaculation was reported by 74.
1 and 90.
3% of patients in group A and B, respectively, versus none in group C.
The QoL score was significant when comparing group A to the other groups; finally, the Q-Max was significant when comparing group C to the other groups.
<b><i>Conclusion:</i></b> For patients bothered by tamsulosin-related abnormal ejaculation, a significant improvement in the QoL, without deviation from the therapeutic purpose of treatment, can be achieved by administration of 0.
4 mg tamsulosin every other day.
Related Results
Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
AbstractTamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not i...
The role of tyrosine hydroxylase within dapoxetine-assisted therapy against premature ejaculation
The role of tyrosine hydroxylase within dapoxetine-assisted therapy against premature ejaculation
Abstract
Background: There are several investigations that have revealed that cerebral dopamine (DA) plays a pivotal role in the occurrence of premature ejaculation (PE). A...
İkinci-dördüncü parmak oranının hayat boyu erken boşalma ile ilişkisi
İkinci-dördüncü parmak oranının hayat boyu erken boşalma ile ilişkisi
OBJECTIVE: The second and fourth finger ratio (2D: 4D) is accepted as an indicator of fetal androgen exposure, and it is stated that the androgenic effect exposed during the fetal ...
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Background: Urolithiasis is a common condition in daily urological practice. Medical Expulsive Therapy (MET) is non-invasive approach for removal of ureteric stone. In MET, alpha-b...
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone
Background: Urolithiasis is a common condition in daily urological practice. Medical Expulsive Therapy (MET) is non-invasive approach for removal of ureteric stone. In MET, alpha-b...
α1A-Adrenoreceptor blockade attenuates myocardial infarction by modulating the integrin-linked kinase/TGF-β/Smad signaling pathways
α1A-Adrenoreceptor blockade attenuates myocardial infarction by modulating the integrin-linked kinase/TGF-β/Smad signaling pathways
Abstract
Background
The role of α1A-adrenoceptor inhibition or its relationship with integrin-linked kinase (ILK) and transforming growth factor-beta (TGF-β)/small mothers...
Comprehensive review of the anatomy and physiology of male ejaculation: Premature ejaculation is not a disease
Comprehensive review of the anatomy and physiology of male ejaculation: Premature ejaculation is not a disease
Human semen contains spermatozoa secreted by the testes and a mixture of components produced by the bulbo‐urethral and Littre (paraurethral) glands, prostate, seminal vesicles, amp...
Visual real-time monitor ejaculatory-orgasm using transrectal ultrasound to identify the cause of Aspermia
Visual real-time monitor ejaculatory-orgasm using transrectal ultrasound to identify the cause of Aspermia
Abstract
Objective
Aspermia is a common ejaculatory disorder having a feeling of orgasm,but no semen after masturbation or sex orgasm. Complete retrograde ejaculation is t...

